Revvity Q1 Earnings Call Highlights

1 hour ago 2

MarketBeat

Tue, May 5, 2026 astatine 7:50 AM CDT 7 min read

Revvity logo

Key Points

Q1 bushed expectations: Revvity posted 3% integrated growth, a 23.6% adjusted operating borderline and adjusted EPS of $1.06 connected $711 cardinal of revenue, repurchased $86 cardinal of stock, generated $115 cardinal of escaped currency travel (97% conversion) and ended the 4th with nett debt/EBITDA of 2.8x.
Planned divestiture of China immunodiagnostics: The portion (~6% of 2025 revenue) is nether a missive of intent with a section purchaser and expected to adjacent by the extremity of adjacent year; absorption volition exclude it from guidance and says the determination should assistance 2026 integrated maturation by ~100 bps and margins by ~30 bps but trim EPS by astir $0.15 (about a 20% simplification successful related EPS impact).
Software/AI absorption and pro forma guidance: Revvity highlighted caller AI/software launches (Xynthetica, BioDesign) with bundle ARR up ~40% YoY, and acceptable pro forma 2026 targets of 3%–4% integrated growth, $2.81–$2.84 cardinal revenue, ~28.4% adjusted operating borderline and $5.20–$5.30 adjusted EPS.
Interested successful Revvity Inc.? Here are 5 stocks we similar better.

Revvity (NYSE:RVTY) reported first-quarter 2026 results that came successful up of its expectations and outlined a planned divestiture of its immunodiagnostics concern successful China, a determination absorption said volition sharpen the company’s absorption and amended maturation and profitability metrics going forward.

First-quarter results apical interior outlook

President and CEO Prahlad Singh said Revvity posted “strong archetypal 4th results” with 3% full institution integrated growth and 23.6% adjusted operating margin, which exceeded the company’s 23% outlook. Adjusted net per stock were $1.06, supra the $1.02–$1.04 outlook implied successful anterior guidance, Singh said.

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Chief Financial Officer Max Krakowiak said quarterly gross totaled $711 million, reflecting 3% integrated growth, including an approximate 3% overseas speech tailwind and a 75 ground constituent incremental publication from the company’s ACD/Labs bundle acquisition. Krakowiak added that the institution repurchased $86 million of shares during the quarter, and generated $115 million of escaped currency flow, which helium said represented 97% conversion of adjusted nett income.

On the equilibrium sheet, Krakowiak said Revvity ended the 4th with a net debt-to-adjusted EBITDA leverage ratio of 2.8x, with 100% fixed-rate debt. He besides noted plans to wage disconnected astir $600 million outstanding connected a Eurobond owed successful mid-July.